Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Life Sciences expects key trial data by mid-2025 - ICYMI
09:31am, Saturday, 31'st May 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's clinical development progress in 2025, highlighting multiple upcoming trial reado
atai Life Sciences to Participate in Upcoming Investor Conferences
08:30am, Thursday, 29'th May 2025
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effec
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
02:58pm, Friday, 23'rd May 2025
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?
10:55am, Thursday, 22'nd May 2025
Atai Life Sciences N.V. (ATAI) reached a significant support level, and could be a good pick for investors from a technical perspective.
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?
10:46am, Thursday, 22'nd May 2025
Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.
atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytech's depression therapy
03:41pm, Tuesday, 20'th May 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of posit
atai Life Sciences announces positive topline data from Phase 2a treatment-resistant depression study
08:44am, Tuesday, 20'th May 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of mebufotenin benzoate, in combinat
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing
atai Life Sciences shares gain momentum ahead of pivotal trial readouts
03:34pm, Thursday, 15'th May 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the
atai Life Sciences builds clinical momentum in first quarter of 2025
08:53am, Wednesday, 14'th May 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key data readouts later this year and into 2026. Recent operational hi
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
07:00am, Wednesday, 14'th May 2025
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments
atai Life Sciences doses first patient in Phase 2 social anxiety trial
09:32am, Tuesday, 13'th May 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral for
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
07:01am, Tuesday, 13'th May 2025
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA
atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI
01:49pm, Saturday, 29'th Mar 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical read
Insiders Make Huge Purchases of These 4 Biotech Stocks
08:40am, Wednesday, 26'th Mar 2025
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h
